Active Surveillance vs. Immediate Intervention for Gleason 3+3 and 3+4: Quantitative Risk Profiling and Genomic Biomarkers

A diagnosis of localized prostate cancer places a patient at a critical crossroads. When biopsy results reveal low-risk or favorable intermediate-risk disease—specifically Gleason 3+3=6 (Grade Group 1) or Gleason 3+4=7 (Grade Group 2)—determining whether to pursue active surveillance or immediate definitive intervention is rarely straightforward.

Historically, treatment was often binary: men were either placed on broad watchful waiting protocols or directed immediately toward radical surgery or radiation. This binary model frequently led to the overtreatment of biologically indolent tumors that posed no threat to life expectancy, or the undertreatment of aggressive sub-clones that were misclassified due to needle biopsy sampling limitations.

Modern urologic oncology relies on precision risk stratification. By pairing multiparametric MRI and targeted fusion biopsies with quantitative tumor volume metrics and tissue-based genomic biomarker assays, clinicians can evaluate the biological behavior of a tumor rather than relying on microscopic cell patterns alone.

In New York, Dr. David B. Samadi brings extensive experience in robotic oncologic surgery and clinical risk evaluation to this decision-making process. Dr. Samadi utilizes comprehensive molecular and anatomical profiling to help patients distinguish between tumors that are safe for close monitoring and those harboring hidden adverse features that warrant early, definitive surgical intervention via the SMART (Samadi Modified Advanced Robotic Technique) protocol.

Deciphering the Pathology: Grade Group 1 (3+3) vs. Grade Group 2 (3+4)

The microscopic architecture of prostate cancer provides the foundation for initial clinical staging:

• Gleason 3+3=6 (Grade Group 1): Composed entirely of well-differentiated, discrete glandular units. True Grade Group 1 disease lacks the biological capacity to metastasize independently to lymph nodes or bone. For nearly all men with low-volume Gleason 3+3 disease, active surveillance is the preferred clinical standard.
• Gleason 3+4=7 (Favorable Intermediate-Risk / Grade Group 2): Represents a mixed histology. The dominant tissue pattern is well-differentiated (Pattern 3), but a secondary component of poorly formed, fused, or cribriform glands (Pattern 4) is present. Because Pattern 4 cells possess invasive and metastatic potential, Gleason 3+4 requires careful secondary profiling to evaluate safety for surveillance.

The Hidden Dangers: When Gleason 3+4 Harbors Aggressive Biology

While some men with Gleason 3+4 disease can be safely monitored, others harbor aggressive disease that calls for prompt treatment. Determining safety depends on specific micro-pathological features:

1. Percentage of Gleason Pattern 4

The total volume of Pattern 4 tissue within the biopsy core is one of the strongest predictors of disease progression. A patient with $< 5\%\text{ to }10\%$ Pattern 4 has a biological profile similar to low-risk disease, whereas a patient with $30\%\text{ to }45\%$ Pattern 4 carries an elevated risk of extraprostatic extension and biochemical recurrence.

2. Cribriform Architecture and Intraductal Carcinoma (IDC-P)

Not all Pattern 4 cells behave the same way. Pathologists look closely for cribriform morphology (sieve-like sheets of cells with perforated lumens) and intraductal carcinoma of the prostate (IDC-P). The presence of cribriform architecture or IDC-P is an adverse feature associated with early metastasis, early biochemical failure, and poor response to surveillance—making immediate intervention the safer clinical choice.

3. Core Involvement and Bilateral Distribution

A solitary core with 1 mm of cancer behaves differently than multiple positive cores spanning both lobes of the gland. High tumor volume across multiple biopsy cores elevates the likelihood of disease upgrading at the time of definitive surgery.

Tissue-Based Genomic Biomarkers: Molecular Risk Profiling

When clinical variables (PSA, digital rectal exam, and biopsy histology) leave the optimal path uncertain, tissue-based genomic classifiers evaluate the RNA expression patterns of the tumor to assess its metastatic potential:

• Decipher® Prostate Biopsy: A 22-RNA biomarker assay that measures gene activation across cell cycle progression, immune evasion, androgen signaling, and cell motility. A low Decipher score ($< 0.45$) indicates a low 5-year metastatic risk, supporting active surveillance. A high Decipher score ($> 0.60$) indicates an aggressive molecular phenotype, suggesting the patient will benefit from early definitive treatment even if the biopsy showed only a small amount of Pattern 4.
• Prolaris® (Cell Cycle Progression – CCP): Measures the expression of 31 genes involved in cell proliferation against 15 housekeeping genes to generate an RNA-based growth score. It provides a direct estimate of 10-year prostate cancer-specific mortality under conservative management versus definitive intervention.
• Oncotype DX® Genomic Prostate Score (GPS): Analyzes 17 genes across four biological pathways (stromal response, cellular organization, proliferation, and androgen pathway) to predict the likelihood of adverse pathology (high-grade disease or extraprostatic extension) at radical prostatectomy.

Comparative Overview: Active Surveillance vs. Immediate Robotic Intervention

The Active Surveillance Protocol: Structured Monitoring

For patients who qualify for active surveillance, the approach is an active, structured monitoring program rather than passive observation:

1. Confirmatory Multiparametric MRI: Performed within 6 to 12 months to verify that no anterior or apical lesions were missed during initial transrectal sampling.
2. Serial PSA and Kinetics: Assessed every three to six months to track PSA velocity and doubling time.
3. Surveillance Biopsy: A repeat targeted fusion biopsy is scheduled between 12 and 24 months to confirm that the tumor has not upgraded to higher-grade patterns.
4. Triggers for Intervention: A transition from surveillance to surgery is recommended if repeat biopsy reveals an upgrade to Gleason $\ge 4+3$, a substantial increase in Pattern 4 percentage, the emergence of cribriform architecture, or a sustained, rapid doubling of PSA.

Conclusion 

Navigating a new diagnosis of Gleason 3+3 or 3+4 prostate cancer does not require choosing between unchecked anxiety and immediate over-treatment. By combining advanced multiparametric imaging, detailed histopathologic review for cribriform patterns, and tissue-based genomic testing, patients can make an evidence-based decision. When surveillance is appropriate, it can be pursued safely; when aggressive biology is uncovered, early intervention with the SMART robotic technique provides definitive cancer control while prioritizing functional preservation.

• Surgeon: Dr. David B. Samadi, MD
• Specialization: Urologic Oncology, Robotic Prostate Cancer Surgery, Precision Risk Profiling
• Key Innovations: Developer of the SMART (Samadi Modified Advanced Robotic Technique) Protocol
• Practice Locations:
  • Midtown Manhattan: 485 Madison Avenue, 21st Floor, New York, NY 10022
  • Long Island: St. Francis Hospital & Heart Center / 2200 Northern Blvd., Suite 120, East Hills, Roslyn, NY 11548
• Official Website:roboticoncology.com
• Direct Consultations: (212) 365-5000